{
  "id": "NCT05568472",
  "criteria": [
    {
      "statement": "Patient that received chemotherapy and have finished it at least 14 days prior to randomization. NOTE: Concomitant maintenance targeted or biologic therapy (e.g., human epidermal growth factor receptor 2 [anti-HER2] therapy, poly-ADP ribose polymerase [PARP] inhibitor therapy, CDK4/6 inhibitor therapy, osteoclast inhibitor therapy) at the time of randomization and/or during study participation is allowed.",
      "type": "inclusion",
      "response": "UNKNOWN",
      "reasoning": [
        "The inclusion criterion specifies that the patient must have received chemotherapy and finished it at least 14 days prior to randomization.",
        "The retrieved medical history does not provide any information about the patient receiving chemotherapy or the timing of its completion.",
        "Without evidence of chemotherapy administration or its timing, it is not possible to definitively determine eligibility based on this criterion."
      ],
      "provenance": []
    },
    {
      "statement": "Patient has a chemotherapy-induced amenorrhea or ovarian failure at time of registration must be planning to start ovarian suppression or ablation if they have recurrence of ovarian function during study participation (circulating estradiol concentration in the premenopausal range or recurrence of menses).",
      "type": "inclusion",
      "response": "UNKNOWN",
      "reasoning": [
        "The inclusion criterion requires the patient to have chemotherapy-induced amenorrhea or ovarian failure at the time of registration and to plan ovarian suppression or ablation if ovarian function recurs during study participation.",
        "The provided medical history does not mention any information about the patient's menstrual history, ovarian function, or estradiol levels.",
        "There is no evidence in the retrieved documents to confirm or refute the presence of chemotherapy-induced amenorrhea or ovarian failure, nor any plans for ovarian suppression or ablation.",
        "Given the lack of relevant information, it is not possible to definitively determine the patient's eligibility based on this criterion."
      ],
      "provenance": []
    },
    {
      "statement": "Has Stage I, II, or III hormone receptor positive breast cancer based on clinical or pathologic evaluation.",
      "type": "inclusion",
      "response": "UNKNOWN",
      "reasoning": [
        "The inclusion criterion requires the patient to have Stage I, II, or III hormone receptor positive breast cancer based on clinical or pathologic evaluation.",
        "The provided medical history includes a CT scan report from 2011, which does not mention any findings related to breast cancer or hormone receptor status.",
        "There is no information in the provided medical history confirming a diagnosis of breast cancer, its stage, or hormone receptor status.",
        "Without additional information or documentation confirming the presence of Stage I, II, or III hormone receptor positive breast cancer, the eligibility cannot be determined."
      ],
      "provenance": []
    },
    {
      "statement": "Patient is taking or planning to take oral estrogen-or progesterone-containing treatments during study participation.",
      "type": "exclusion",
      "response": "UNKNOWN",
      "reasoning": [
        "The exclusion criterion specifies that the patient is excluded if they are taking or planning to take oral estrogen- or progesterone-containing treatments during study participation.",
        "The provided medical history does not mention any information about the patient taking or planning to take oral estrogen- or progesterone-containing treatments.",
        "Without explicit information about the patient's current or planned medication regimen, it is not possible to definitively determine whether the patient meets this exclusion criterion."
      ],
      "provenance": []
    },
    {
      "statement": "Patient has ovarian function (estradiol above the postmenopausal range) must be planning to undergo ovarian suppression or ablation concomitantly with oral ET medication, starting before or at the same time as oral ET initiation. Participants with chemotherapy-induced amenorrhea or ovarian failure at time of registration must be planning to start ovarian suppression or ablation if they have recurrence of ovarian function during study participation (circulating estradiol concentration in the premenopausal range or recurrence of menses).",
      "type": "inclusion",
      "response": "UNKNOWN",
      "reasoning": [
        "The inclusion criterion requires the patient to have ovarian function (estradiol above the postmenopausal range) and to plan ovarian suppression or ablation concomitantly with oral ET medication.",
        "Alternatively, if the patient has chemotherapy-induced amenorrhea or ovarian failure, they must plan ovarian suppression or ablation if ovarian function recurs during study participation.",
        "The provided medical history does not include any information about estradiol levels, ovarian function, or plans for ovarian suppression or ablation.",
        "Without information on estradiol levels or ovarian function, it is not possible to determine whether the patient meets the inclusion criterion."
      ],
      "provenance": []
    },
    {
      "statement": "Patient has a complete medical history within 60 days prior to randomization.",
      "type": "inclusion",
      "response": "INELIGIBLE",
      "reasoning": [
        "The inclusion criterion requires the patient to have a complete medical history within 60 days prior to randomization.",
        "The provided medical history includes a diagnostic report from 2011, which is far outside the 60-day window prior to the current date (2024-05-18).",
        "No other medical records or diagnostic reports within the required timeframe are provided.",
        "Based on the available information, the patient does not meet the inclusion criterion."
      ],
      "provenance": [
        {
          "source": "DiagnosticReport/DiagnosticReportID",
          "content": "CT THORAX ABDOMEN PELVIS WITH CONTRAST was measured on 2011-09-28."
        }
      ]
    },
    {
      "statement": "Had a serum or plasma estradiol and/or follicle stimulating hormone (FSH) concentration consistent with premenopausal status (based on institutional standards) within the 12 months before breast cancer diagnosis or when checked after breast cancer diagnosis.",
      "type": "inclusion",
      "response": "UNKNOWN",
      "reasoning": [
        "The inclusion criterion requires evidence of serum or plasma estradiol and/or follicle stimulating hormone (FSH) concentrations consistent with premenopausal status within the 12 months before or after breast cancer diagnosis.",
        "The provided medical history does not include any information about estradiol or FSH levels, nor does it mention breast cancer diagnosis or timing.",
        "Without specific lab results or relevant clinical notes addressing estradiol or FSH levels, it is impossible to determine whether the patient meets this criterion."
      ],
      "provenance": []
    },
    {
      "statement": "Patient is able to complete Patient-Reported Outcome (PRO) instruments in English or Spanish.",
      "type": "inclusion",
      "response": "UNKNOWN",
      "reasoning": [
        "The inclusion criterion requires the patient to be able to complete Patient-Reported Outcome (PRO) instruments in English or Spanish.",
        "The provided medical history does not contain any information about the patient's language proficiency or ability to complete PRO instruments.",
        "Without explicit evidence of the patient's language skills or ability to complete PRO instruments, it is not possible to determine eligibility for this criterion."
      ],
      "provenance": []
    },
    {
      "statement": "Patient has started initial treatment with standard of care oral endocrine therapy (ET) (i.e., tamoxifen, anastrozole, exemestane, or letrozole; within 14 days prior to randomization or be planning to start initial treatment with standard of care oral ET within 14 days after randomization.",
      "type": "inclusion",
      "response": "UNKNOWN",
      "reasoning": [
        "The inclusion criterion requires the patient to have started initial treatment with standard of care oral endocrine therapy (ET) within 14 days prior to randomization or be planning to start initial treatment within 14 days after randomization.",
        "The provided medical history does not mention any information about the patient starting or planning to start oral endocrine therapy (ET) such as tamoxifen, anastrozole, exemestane, or letrozole.",
        "Without explicit information about ET initiation or plans for ET initiation, it is not possible to determine eligibility based on this criterion."
      ],
      "provenance": []
    },
    {
      "statement": "Patient is planning to become pregnant during the 80 weeks of study participation.",
      "type": "exclusion",
      "response": "UNKNOWN",
      "reasoning": [
        "The exclusion criterion specifies that the patient is planning to become pregnant during the 80 weeks of study participation.",
        "The provided medical history does not contain any information about the patient's pregnancy plans or intentions.",
        "Without explicit information regarding the patient's plans to become pregnant, it is not possible to definitively assess this criterion."
      ],
      "provenance": []
    },
    {
      "statement": "Had a menstrual period (by self-report) within the 12 months before breast cancer diagnosis.",
      "type": "inclusion",
      "response": "UNKNOWN",
      "reasoning": [
        "The inclusion criterion requires the patient to have had a menstrual period within the 12 months before their breast cancer diagnosis.",
        "The provided medical history does not mention the patient's breast cancer diagnosis date or any information about their menstrual history.",
        "Without information on the timing of the breast cancer diagnosis or self-reported menstrual history, it is not possible to determine if the patient meets this criterion."
      ],
      "provenance": []
    },
    {
      "statement": "Patient has started or plan to start treatment with an aromatase inhibitor during study participation must not have received prior aromatase inhibitor therapy for treatment or prevention of breast cancer.",
      "type": "exclusion",
      "response": "UNKNOWN",
      "reasoning": [
        "The exclusion criterion specifies that the patient must not have received prior aromatase inhibitor therapy for treatment or prevention of breast cancer.",
        "The provided medical history does not mention any prior aromatase inhibitor therapy or plans to start such therapy.",
        "There is no evidence in the retrieved documents indicating the patient has received aromatase inhibitor therapy for breast cancer treatment or prevention.",
        "Given the absence of relevant information, the patient cannot be definitively excluded based on this criterion."
      ],
      "provenance": []
    },
    {
      "statement": "Patient must have completed surgery for treatment of breast cancer at least 14 days prior to randomization. NOTE: Concomitant radiotherapy at the time of randomization and/or during study participation is allowed.",
      "type": "inclusion",
      "response": "UNKNOWN",
      "reasoning": [
        "The inclusion criterion requires the patient to have completed surgery for treatment of breast cancer at least 14 days prior to randomization.",
        "The provided medical history does not mention any surgery for breast cancer or any history of breast cancer diagnosis.",
        "Without evidence of breast cancer surgery or diagnosis, it is not possible to determine if the patient meets this criterion."
      ],
      "provenance": []
    },
    {
      "statement": "Patient has started or plan to start treatment with tamoxifen during study participation and havn't received prior tamoxifen for treatment or prevention of breast cancer.",
      "type": "exclusion",
      "response": "UNKNOWN",
      "reasoning": [
        "The exclusion criterion specifies that the patient must not start or plan to start tamoxifen during study participation unless they have received prior tamoxifen for treatment or prevention of breast cancer.",
        "The provided medical history does not mention any prior use of tamoxifen for treatment or prevention of breast cancer.",
        "There is no information in the provided notes about the patient starting or planning to start tamoxifen during study participation.",
        "Due to the lack of information about tamoxifen use or plans, it is not possible to definitively determine whether the patient meets the exclusion criterion."
      ],
      "provenance": []
    },
    {
      "statement": "Patient receives additional anti-cancer treatments (i.e., experimental therapy, immunotherapy, biologics, etc.) as part of another clinical trial.",
      "type": "exclusion",
      "response": "ELIGIBLE",
      "reasoning": [
        "The exclusion criterion specifies that the patient should not be receiving additional anti-cancer treatments as part of another clinical trial.",
        "The provided medical history does not mention any participation in another clinical trial or the receipt of experimental therapy, immunotherapy, biologics, or other anti-cancer treatments.",
        "There is no evidence in the retrieved documents to suggest that the patient is currently receiving such treatments.",
        "Based on the available information, the patient does not meet the exclusion criterion."
      ],
      "provenance": []
    },
    {
      "statement": "Patient has a distant metastatic breast cancer.",
      "type": "exclusion",
      "response": "ELIGIBLE",
      "reasoning": [
        "The exclusion criterion specifies that the patient must have distant metastatic breast cancer to be excluded.",
        "The provided CT Thorax Abdomen Pelvis report from 2011 does not indicate any evidence of distant metastases or abnormalities in the thorax, abdomen, or pelvis.",
        "There is no mention of breast cancer or metastatic disease in the provided medical history.",
        "Based on the available information, there is no evidence to suggest the patient meets the exclusion criterion."
      ],
      "provenance": [
        {
          "source": "DiagnosticReport/DiagnosticReportID",
          "content": "The CT scan revealed the following findings: The thorax: No evidence of pulmonary embolism or pneumonia was seen. The lungs were clear, with no evidence of consolidation or effusion. The abdomen: The liver, spleen, and kidneys were normal in size and shape. The pancreas was normal, with no evidence of pancreatitis or pancreatic mass. The small bowel was normal, with no evidence of obstruction or inflammatory changes. The large bowel was normal, with no evidence of diverticulitis or inflammatory changes. The pelvis: The pelvis was normal, with no evidence of fracture or inflammatory changes."
        }
      ]
    },
    {
      "statement": "Patient has a non-breast malignancy for which they are currently receiving treatment.",
      "type": "exclusion",
      "response": "ELIGIBLE",
      "reasoning": [
        "The exclusion criterion specifies that the patient must have a non-breast malignancy for which they are currently receiving treatment.",
        "The provided medical history includes a CT scan report from 2011, which does not indicate any malignancy in the thorax, abdomen, or pelvis.",
        "There is no mention of a current diagnosis or treatment for a non-breast malignancy in the provided information.",
        "The absence of evidence regarding a non-breast malignancy or its treatment suggests the patient does not meet the exclusion criterion."
      ],
      "provenance": [
        {
          "source": "DiagnosticReport/DiagnosticReportID",
          "content": "The CT scan revealed the following findings: The thorax: No evidence of pulmonary embolism or pneumonia was seen. The lungs were clear, with no evidence of consolidation or effusion. The abdomen: The liver, spleen, and kidneys were normal in size and shape. The pancreas was normal, with no evidence of pancreatitis or pancreatic mass. The small bowel was normal, with no evidence of obstruction or inflammatory changes. The large bowel was normal, with no evidence of diverticulitis or inflammatory changes. The pelvis: The pelvis was normal, with no evidence of fracture or inflammatory changes."
        }
      ]
    }
  ]
}